MARKET NEWS

TCR² Therapeutics Establishes Commercial-Scale Cell Therapy Manufacturing Facility
Provectus Biopharmaceuticals Receives Notice of Allowance for Adult Solid Tumor Cancer Combination Therapy Patent
Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection
Micropore Technologies Appoints New Sales Development Director for the Americas
BridgeBio Pharma’s Affiliate QED Therapeutics & Helsinn Group Announce Strategic Co-Development & Commercialization Agreement
Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement With AstraZeneca to Include Drug Product Manufacturing

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Recipharm is a leading contract development and manufacturing organisation (CDMO) headquartered in Stockholm, Sweden. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering for our customers. Employing around 9,000 people, we are focused on supporting pharmaceutical companies with our full service offering, taking products from early development through to commercial production. For over 25 years we have been there for our clients throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again. Despite our growing global footprint, we conduct our business as we always have and continue to deliver value for money with each customer’s needs firmly at the heart of all that we do. That’s the Recipharm way. Click here for more.

VIDEO SPOTLIGHT – Micropore’s award-winning new technology for creating advanced formulations produces emulsions, precision microcapsules and microparticles, at volume, with a particle size distribution only previously possible using microfluidics. The patented membrane-based system enables formulations to be reliably and economically produced at any scale from lab experiments and pilot runs through to kilotonne manufacturing. Click here for video.

 

  EXCLUSIVE ONLINE CONTENT

Tarsus Pharmaceuticals & LianBio Announce Strategic Development & Commercialization Partnership 

Tarsus Pharmaceuticals & LianBio Announce Strategic Development & Commercialization Partnership 

Tarsus Pharmaceuticals, Inc. and LianBio recently announced a strategic partnership to develop and commercialize TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau)…..

Syneos Health Partners With Science 37 to Transform Clinical Trials

Syneos Health Partners With Science 37 to Transform Clinical Trials

Syneos Health and Science 37 recently announced a strategic partnership to enable enhanced decentralized clinical trial delivery…..

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

Pfizer Inc. and BioNTech SE recently announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2….

Ajinomoto & Bright Peak Therapeutics Enter Research Collaboration & License Agreement 

Ajinomoto & Bright Peak Therapeutics Enter Research Collaboration & License Agreement 

Ajinomoto Co., Inc. and Bright Peak Therapeutics Inc. recently announced a research collaboration and exclusive license agreement to incorporate AJICAP, Ajinomoto Co.’s proprietary….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 14 – Prefilled Syringes
April 21 – Inhalation Drug Delivery